Skip to main content
SpringerLink
Log in
Book cover

Hormone Use and Abuse by Athletes pp 63–87Cite as

Androgen Abuse

  • Chapter
  • First Online:

  • 1084 Accesses

Part of the book series: Endocrine Updates ((ENDO,volume 29))

Abstract

The decade of the 1930s was marked by two notable milestones in Endocrinologythe discovery of testosterone as the predominant androgen in humans and its chemical synthesis; these discoveries ushered in the era of the rational hormone replacement therapy of androgen-deficient men. However, two powerful myths have pervaded the academic community for more than seven decades. First, in spite of compelling empiric evidence from the experience of athletes and recreational body builders worldwide, the academic community continued to assert that androgens do not increase muscle mass or strength [1]. Fortunately.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Wilson JD. Androgen abuse by athletes. Endocr Rev. 1988; 9:181–199.

    PubMed  CAS  Google Scholar 

  2. Bhasin S, Calof O, Storer TW, et al. Drug insights: anabolic applications of testosterone and selective androgen receptor modulators in aging and chronic illness. Nat Clin Pract Endocrinol Metab. 2006; 2:133–140.

    Google Scholar 

  3. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2006; 91:1995–2010.

    PubMed  CAS  Google Scholar 

  4. Yesalis CE, III, Bahrke MS, Kopstein AN, Baruskiewicz CK. Incidence onabolic steroid use: a discussion of methodological issues. In: Yesalis CE, III ed. 2000. Anabolic steroids in sports and exercise, Second ed. Champaign, IL: Human Kinetics; 73–115.

    Google Scholar 

  5. Yesalis CE, Barsukiewicz CK, Kopstein AN, Bahrke MS. Trends in anabolic-androgenic steroid use among adolescents. Arch Pediatr Adolesc Med. 1997; 151:1197–1206.

    PubMed  CAS  Google Scholar 

  6. Yesalis CE, Kennedy NJ, Kopstein AN, Bahrke MS. Anabolic-androgenic steroid use in the United States. JAMA. 1993; 270:1217–1221.

    PubMed  CAS  Google Scholar 

  7. Hoffman JR, Kraemer WJ, Bhasin S, Storer T, Ratamess NA, Haff GG, Willoughby DS, Rogol AD. Position stand on androgen and human growth hormone use. J Strength Cond Res/National Strength & Conditioning Association. 2009; 23:S1–S59.

    Google Scholar 

  8. Medicine ACoS. Position stand: the use of anabolic-androgenic steroids in sports. Med Sci Sports Exerc. 1987; 19:534–539.

    Google Scholar 

  9. Catlin DH, Fitch KD, Ljungqvist A. Medicine and science in the fight against doping in sport. J Intern Med. 2008; 264:99–114.

    PubMed  CAS  Google Scholar 

  10. Kopera H. The history of anabolic steroids and a review of clinical experience with anabolic steroids. Acta Endocrinol Suppl (Copenh). 1985; 271:11–18.

    CAS  Google Scholar 

  11. McDuff DR, Baron D. Substance use in athletics: a sports psychiatry perspective. Clin Sports Med. 2005; 24:885–897, ix–x.

    PubMed  Google Scholar 

  12. Noakes TD. Tainted glory – doping and athletic performance. N Engl J Med. 2004; 351:847–849.

    PubMed  CAS  Google Scholar 

  13. Prendergast HM, Bannen T, Erickson TB, Honore KR. The toxic torch of the modern Olympic Games. Vet Hum Toxicol. 2003; 45:97–102.

    PubMed  Google Scholar 

  14. Wadler GI. Drug use update. Med Clin North Am. 1994; 78:439–455.

    PubMed  CAS  Google Scholar 

  15. Shackleton C. Steroid analysis and doping control 1960–1980: scientific developments and personal anecdotes. Steroids. 2009; 74:288–295.

    PubMed  CAS  Google Scholar 

  16. Wade N. Anabolic steroids: doctors denounce them, but athletes aren’t listening. Science. 1972; 176:1399–1403.

    PubMed  CAS  Google Scholar 

  17. Yesalis CE, Courson SP, Wright JE. History of anabolic steroid use in sport and exercise. In: Yesalis CE ed. Anabolic steroids in sports and exercise. 2000. Champaign, IL: Human Kinetics; 51–72.

    Google Scholar 

  18. Yamaguchi R, Johnston LD, O’Malley PM. Relationship between student illicit drug use and school drug-testing policies. J Sch Health. 2003; 73:159–164.

    PubMed  Google Scholar 

  19. Clifford PR, Edmundson E, Koch WR, Dodd BG. Discerning the epidemiology of drug use among a sample of college students. J Drug Educ. 1989; 19:209–223.

    PubMed  CAS  Google Scholar 

  20. McCabe SE, Brower KJ, West BT, Nelson TF, Wechsler H. Trends in non-medical use of anabolic steroids by U.S. college students: results from four national surveys. Drug Alcohol Depend. 2007; 90:243–251.

    PubMed  Google Scholar 

  21. Evans NA. Gym and tonic: a profile of 100 male steroid users. Br J Sports Med. 1997; 31:54–58.

    PubMed  CAS  Google Scholar 

  22. Evans NA. Local complications of self administered anabolic steroid injections. Br J Sports Med. 1997; 31:349–350.

    PubMed  CAS  Google Scholar 

  23. Pope HG, Jr., Katz DL. Psychiatric and medical effects of anabolic-androgenic steroid use. A controlled study of 160 athletes. Arch Gen Psychiatry. 1994; 51:375–382.

    PubMed  CAS  Google Scholar 

  24. Parkinson AB, Evans NA. Anabolic androgenic steroids: a survey of 500 users. Med Sci Sports Exerc. 2006; 38:644–651.

    PubMed  CAS  Google Scholar 

  25. Evans NA. Current concepts in anabolic-androgenic steroids. Am J Sports Med. 2004; 32:534–542.

    PubMed  Google Scholar 

  26. Bhasin S, Storer TW, Berman N, Yarasheski KE, Clevenger B, Phillips J, Lee WP, Bunnell TJ, Casaburi R. Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab. 1997; 82:407–413.

    PubMed  CAS  Google Scholar 

  27. Brodsky IG, Balagopal P, Nair KS. Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men – a clinical research center study. J Clin Endocrinol Metab. 1996; 81:3469–3475.

    PubMed  CAS  Google Scholar 

  28. Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ, Weber T, Berman N, Hull L, Swerdloff RS. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab. 2004; 89:2085–2098.

    PubMed  CAS  Google Scholar 

  29. Snyder PJ, Peachey H, Berlin JA, Hannoush P, Haddad G, Dlewati A, Santanna J, Loh L, Lenrow DA, Holmes JH, Kapoor SC, Atkinson LE, Strom BL. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab. 2000; 85:2670–2677.

    PubMed  CAS  Google Scholar 

  30. Steidle C, Schwartz S, Jacoby K, Sebree T, Smith T, Bachand R. AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J Clin Endocrinol Metab. 2003; 88:2673–2681.

    PubMed  CAS  Google Scholar 

  31. Mauras N, Hayes V, Welch S, Rini A, Helgeson K, Dokler M, Veldhuis JD, Urban RJ. Testosterone deficiency in young men: marked alterations in whole body protein kinetics, strength, and adiposity. J Clin Endocrinol Metab. 1998; 83:1886–1892.

    PubMed  CAS  Google Scholar 

  32. Bhasin S, Storer TW, Berman N, Callegari C, Clevenger B, Phillips J, Bunnell TJ, Tricker R, Shirazi A, Casaburi R. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med. 1996; 335:1–7.

    PubMed  CAS  Google Scholar 

  33. Hartgens F, Kuipers H. Effects of androgenic-anabolic steroids in athletes. Sports Med. 2004; 34:513–554.

    PubMed  Google Scholar 

  34. Bhasin S, Woodhouse L, Casaburi R, Singh AB, Bhasin D, Berman N, Chen X, Yarasheski KE, Magliano L, Dzekov C, Dzekov J, Bross R, Phillips J, Sinha-Hikim I, Shen R, Storer TW. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab. 2001; 281:E1172–E1181.

    PubMed  CAS  Google Scholar 

  35. Woodhouse LJ, Reisz-Porszasz S, Javanbakht M, Storer TW, Lee M, Zerounian H, Bhasin S. Development of models to predict anabolic response to testosterone administration in healthy young men. Am J Physiol Endocrinol Metab. 2003; 284:E1009–E1017.

    PubMed  CAS  Google Scholar 

  36. Bhasin S, Storer TW, Javanbakht M, Berman N, Yarasheski KE, Phillips J, Dike M, Sinha-Hikim I, Shen R, Hays RD, Beall G. Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels. JAMA. 2000; 283:763–770.

    PubMed  CAS  Google Scholar 

  37. Grinspoon S, Corcoran C, Askari H, Schoenfeld D, Wolf L, Burrows B, Walsh M, Hayden D, Parlman K, Anderson E, Basgoz N, Klibanski A. Effects of androgen administration in men with the AIDS wasting syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1998; 129:18–26.

    PubMed  CAS  Google Scholar 

  38. Grinspoon S, Corcoran C, Stanley T, Katznelson L, Klibanski A. Effects of androgen administration on the growth hormone-insulin-like growth factor I axis in men with acquired immunodeficiency syndrome wasting. J Clin Endocrinol Metab. 1998; 83:4251–4256.

    PubMed  CAS  Google Scholar 

  39. Casaburi R, Bhasin S, Cosentino L, Porszasz J, Somfay A, Lewis MI, Fournier M, Storer TW. Effects of testosterone and resistance training in men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004; 170:870–878.

    PubMed  Google Scholar 

  40. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Lenrow DA, Holmes JH, Dlewati A, Santanna J, Rosen CJ, Strom BL. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab. 1999; 84:2647–2653.

    PubMed  CAS  Google Scholar 

  41. Page ST, Amory JK, Bowman FD, Anawalt BD, Matsumoto AM, Bremner WJ, Tenover JL. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab. 2004; 90(3):1502–1510.

    PubMed  Google Scholar 

  42. Kenny AM, Prestwood KM, Gruman CA, Marcello KM, Raisz LG. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci. 2001; 56:M266–M272.

    PubMed  CAS  Google Scholar 

  43. Storer TW, Magliano L, Woodhouse L, Lee ML, Dzekov C, Dzekov J, Casaburi R, Bhasin S. Testosterone dose-dependently increases maximal voluntary strength and leg power, but does not affect fatigability or specific tension. J Clin Endocrinol Metab. 2003; 88:1478–1485.

    PubMed  CAS  Google Scholar 

  44. Coviello AD, Kaplan B, Lakshman KM, Chen T, Singh AB, Bhasin S. Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. J Clin Endocrinol Metab. 2008; 93:914–919.

    PubMed  CAS  Google Scholar 

  45. Blanco CE, Popper P, Micevych P. Anabolic-androgenic steroid induced alterations in choline acetyltransferase messenger RNA levels of spinal cord motoneurons in the male rat. Neuroscience. 1997; 78:873–882.

    PubMed  CAS  Google Scholar 

  46. Blanco CE, Zhan WZ, Fang YH, Sieck GC. Exogenous testosterone treatment decreases diaphragm neuromuscular transmission failure in male rats. J Appl Physiol. 2001; 90:850–856.

    PubMed  CAS  Google Scholar 

  47. Leslie M, Forger NG, Breedlove SM. Sexual dimorphism and androgen effects on spinal motoneurons innervating the rat flexor digitorum brevis. Brain Res. 1991; 561:269–273.

    PubMed  CAS  Google Scholar 

  48. Sinha-Hikim I, Artaza J, Woodhouse L, Gonzalez-Cadavid N, Singh AB, Lee MI, Storer TW, Casaburi R, Shen R, Bhasin S. Testosterone-induced increase in muscle size in healthy young men is associated with muscle fiber hypertrophy. Am J Physiol Endocrinol Metab. 2002; 283:E154–E164.

    PubMed  CAS  Google Scholar 

  49. Kadi F. Cellular and molecular mechanisms responsible for the action of testosterone on human skeletal muscle. A basis for illegal performance enhancement. Br J Pharmacol. 2008; 154:522–528.

    PubMed  CAS  Google Scholar 

  50. Kadi F, Bonnerud P, Eriksson A, Thornell LE. The expression of androgen receptors in human neck and limb muscles: effects of training and self-administration of androgenic-anabolic steroids. Histochem Cell Biol. 2000; 113:25–29.

    PubMed  CAS  Google Scholar 

  51. Sinha-Hikim I, Roth SM, Lee MI, Bhasin S. Testosterone-induced muscle hypertrophy is associated with an increase in satellite cell number in healthy, young men. Am J Physiol Endocrinol Metab. 2003; 285:E197–E205.

    PubMed  CAS  Google Scholar 

  52. Sinha-Hikim I, Taylor WE, Gonzalez-Cadavid NF, Zheng W, Bhasin S. Androgen receptor in human skeletal muscle and cultured muscle satellite cells: up-regulation by androgen treatment. J Clin Endocrinol Metab. 2004; 89:5245–5255.

    PubMed  CAS  Google Scholar 

  53. MacLean HE, Chiu WS, Ma C, McManus JF, Davey RA, Cameron R, Notini AJ, Zajac JD. A floxed allele of the androgen receptor gene causes hyperandrogenization in male mice. Physiol Genomics. 2008; 33:133–137.

    PubMed  CAS  Google Scholar 

  54. Ophoff J, Van Proeyen K, Callewaert F, De Gendt K, De Bock K, Vanden Bosch A, Verhoeven G, Hespel P, Vanderschueren D. Androgen signaling in myocytes contributes to the maintenance of muscle mass and fiber type regulation but not to muscle strength or fatigue. Endocrinology. 2009; 150:3558–3566.

    PubMed  CAS  Google Scholar 

  55. Singh R, Artaza JN, Taylor WE, Braga M, Yuan X, Gonzalez-Cadavid NF, Bhasin S. Testosterone inhibits adipogenic differentiation in 3T3-L1 cells: nuclear translocation of androgen receptor complex with beta-catenin and T-cell factor 4 may bypass canonical Wnt signaling to down-regulate adipogenic transcription factors. Endocrinology. 2006; 147:141–154.

    PubMed  CAS  Google Scholar 

  56. Singh R, Artaza JN, Taylor WE, Gonzalez-Cadavid NF, Bhasin S. Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H 10T1/2 pluripotent cells through an androgen receptor-mediated pathway. Endocrinology. 2003; 144:5081–5088.

    PubMed  CAS  Google Scholar 

  57. Singh R, Bhasin S, Braga M, Artaza JN, Pervin S, Taylor WE, Krishnan V, Sinha SK, Rajavashisth TB, Jasuja R. Regulation of myogenic differentiation by androgens: cross talk between androgen receptor/beta-catenin and follistatin/transforming growth factor-beta ­signaling pathways. Endocrinology. 2009; 150:1259–1268.

    PubMed  CAS  Google Scholar 

  58. Jasuja R, Ulloor J, Yengo CM, Choong K, Istomin AY, Livesay DR, Jacobs DJ, Swerdloff RS, Miksovska J, Larsen RW, Bhasin S. Kinetic and thermodynamic characterization of dihydrotestosterone-induced conformational perturbations in androgen receptor ligand-binding domain. Mol Endocrinol. 2009; 23:1231–1241.

    PubMed  CAS  Google Scholar 

  59. Kochakian CD, Cohn L, et al. Effect of testosterone propionate on nitrogen and chloride excretion and body weight of castrated rats during recovery from fasting. Am J Physiol. 1948; 155:272–277.

    PubMed  CAS  Google Scholar 

  60. Kochakian CD, Costa G. The effect of testosterone propionate on the protein and carbohydrate metabolism in the depancreatized-castrated dog. Endocrinology. 1959; 65:298–309.

    PubMed  CAS  Google Scholar 

  61. Urban RJ, Bodenburg YH, Gilkison C, Foxworth J, Coggan AR, Wolfe RR, Ferrando A. Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis. Am J Physiol. 1995; 269:E820–E826.

    PubMed  CAS  Google Scholar 

  62. Ferrando AA, Sheffield-Moore M, Paddon-Jones D, Wolfe RR, Urban RJ. Differential ­anabolic effects of testosterone and amino acid feeding in older men. J Clin Endocrinol Metab. 2003; 88:358–362.

    PubMed  CAS  Google Scholar 

  63. Ferrando AA, Sheffield-Moore M, Yeckel CW, Gilkison C, Jiang J, Achacosa A, Lieberman SA, Tipton K, Wolfe RR, Urban RJ. Testosterone administration to older men improves muscle function: molecular and physiological mechanisms. Am J Physiol Endocrinol Metab. 2002; 282:E601–E607.

    PubMed  CAS  Google Scholar 

  64. Choong K, Lakshman KM, Bhasin S. The physiological and pharmacological basis for the ergogenic effects of androgens in elite sports. Asian J Androl. 2008; 10:351–363.

    PubMed  CAS  Google Scholar 

  65. Strauss RH, Liggett MT, Lanese RR. Anabolic steroid use and perceived effects in ten weight-trained women athletes. JAMA. 1985; 253:2871–2873.

    PubMed  CAS  Google Scholar 

  66. Strauss RH, Yesalis CE. Anabolic steroids in the athlete. Annu Rev Med. 1991; 42:449–457.

    PubMed  CAS  Google Scholar 

  67. Bahrke MS, Wright JE, Strauss RH, Catlin DH. Psychological moods and subjectively ­perceived behavioral and somatic changes accompanying anabolic-androgenic steroid use. Am J Sports Med. 1992; 20:717–724.

    PubMed  CAS  Google Scholar 

  68. Bahrke MS, Wright JE, O’Connor JS, Strauss RH, Catlin DH. Selected psychological characteristics of anabolic-androgenic steroid users. N Engl J Med. 1990; 323:834–835.

    PubMed  CAS  Google Scholar 

  69. Parssinen M, Kujala U, Vartiainen E, Sarna S, Seppala T. Increased premature mortality of competitive powerlifters suspected to have used anabolic agents. Int J Sports Med. 2000; 21:225–227.

    PubMed  CAS  Google Scholar 

  70. Glazer G. Atherogenic effects of anabolic steroids on serum lipid levels. A literature review. Arch Intern Med. 1991; 151:1925–1933.

    PubMed  CAS  Google Scholar 

  71. Daly RC, Su TP, Schmidt PJ, Pagliaro M, Pickar D, Rubinow DR. Neuroendocrine and behavioral effects of high-dose anabolic steroid administration in male normal volunteers. Psychoneuroendocrinology. 2003; 28:317–331.

    PubMed  CAS  Google Scholar 

  72. Payne AH, Quinn PG, Rani CS. Regulation of microsome cytochrome P-450 enzymes and testosterone production in Leydig cells. Recent Prog Horm Res. 1985; 41:153–197.

    PubMed  CAS  Google Scholar 

  73. Ansell JE, Tiarks C, Fairchild VK. Coagulation abnormalities associated with the use of anabolic steroids. Am Heart J. 1993; 125:367–371.

    PubMed  CAS  Google Scholar 

  74. Soe KL, Soe M, Gluud C. Liver pathology associated with the use of anabolic-androgenic steroids. Liver. 1992; 12:73–79.

    PubMed  CAS  Google Scholar 

  75. Dickerman RD, Pertusi RM, Zachariah NY, Dufour DR, McConathy WJ. Anabolic steroid-induced hepatotoxicity: is it overstated? Clin J Sport Med. 1999; 9:34–39.

    PubMed  CAS  Google Scholar 

  76. Pertusi R, Dickerman RD, McConathy WJ. Evaluation of aminotransferase elevations in a bodybuilder using anabolic steroids: hepatitis or rhabdomyolysis? J Am Osteopath Assoc. 2001; 101:391–394.

    PubMed  CAS  Google Scholar 

  77. Green GA, Uryasz FD, Petr TA, Bray CD. NCAA study of substance use and abuse habits of college student-athletes. Clin J Sport Med. 2001; 11:51–56.

    PubMed  CAS  Google Scholar 

  78. Petersson A, Garle M, Holmgren P, Druid H, Krantz P, Thiblin I. Toxicological findings and manner of death in autopsied users of anabolic androgenic steroids. Drug Alcohol Depend. 2006; 81:241–249.

    PubMed  CAS  Google Scholar 

  79. Petersson A, Garle M, Granath F, Thiblin I. Morbidity and mortality in patients testing positively for the presence of anabolic androgenic steroids in connection with receiving medical care. A controlled retrospective cohort study. Drug Alcohol Depend. 2006; 81:215–220.

    PubMed  CAS  Google Scholar 

  80. Thiblin I, Lindquist O, Rajs J. Cause and manner of death among users of anabolic androgenic steroids. J Forensic Sci. 2000; 45:16–23.

    PubMed  CAS  Google Scholar 

  81. Thiblin I, Runeson B, Rajs J. Anabolic androgenic steroids and suicide. Ann Clin Psychiatry. 1999; 11:223–231.

    PubMed  CAS  Google Scholar 

  82. Melchert RB, Welder AA. Cardiovascular effects of androgenic-anabolic steroids. Med Sci Sports Exerc. 1995; 27:1252–1262.

    PubMed  CAS  Google Scholar 

  83. Bonetti A, Tirelli F, Catapano A, Dazzi D, Dei Cas A, Solito F, Ceda G, Reverberi C, Monica C, Pipitone S, Elia G, Spattini M, Magnati G. Side effects of anabolic androgenic steroids abuse. Int J Sports Med. 2007; 29(8):679–687.

    PubMed  Google Scholar 

  84. Dhar R, Stout CW, Link MS, Homoud MK, Weinstock J, Estes NA, III. Cardiovascular toxicities of performance-enhancing substances in sports. Mayo Clin Proc. 2005; 80:1307–1315.

    PubMed  CAS  Google Scholar 

  85. Karila TA, Karjalainen JE, Mantysaari MJ, Viitasalo MT, Seppala TA. Anabolic androgenic steroids produce dose-dependant increase in left ventricular mass in power atheletes, and this effect is potentiated by concomitant use of growth hormone. Int J Sports Med. 2003; 24:337–343.

    PubMed  CAS  Google Scholar 

  86. Sullivan ML, Martinez CM, Gennis P, Gallagher EJ. The cardiac toxicity of anabolic steroids. Prog Cardiovas Dis. 1998; 41:1–15.

    CAS  Google Scholar 

  87. Nieminen MS, Ramo MP, Viitasalo M, Heikkila P, Karjalainen J, Mantysaari M, Heikkila J. Serious cardiovascular side effects of large doses of anabolic steroids in weight lifters. Eur Heart J. 1996; 17:1576–1583.

    PubMed  CAS  Google Scholar 

  88. Maravelias C, Dona A, Stefanidou M, Spiliopoulou C. Adverse effects of anabolic steroids in athletes. A constant threat. Toxicol Lett. 2005; 158:167–175.

    PubMed  CAS  Google Scholar 

  89. Basaria S, Nguyen T, Rosenson RS, Dobs AS. Effect of methyl testosterone administration on plasma viscosity in postmenopausal women. Clin Endocrinol (Oxf). 2002; 57:209–214.

    CAS  Google Scholar 

  90. Braga-Basaria M, Muller DC, Carducci MA, Dobs AS, Basaria S. Lipoprotein profile in men with prostate cancer undergoing androgen deprivation therapy. Int J Impot Res. 2006; 18:494–498.

    PubMed  CAS  Google Scholar 

  91. Dobs AS, Bachorik PS, Arver S, Meikle AW, Sanders SW, Caramelli KE, Mazer NA. Interrelationships among lipoprotein levels, sex hormones, anthropometric parameters, and age in hypogonadal men treated for 1 year with a permeation-enhanced testosterone transdermal system. J Clin Endocrinol Metab. 2001; 86:1026–1033.

    PubMed  CAS  Google Scholar 

  92. Friedl KE. Reappraisal of the health risks associated with the use of high doses of oral and injectable androgenic steroids. NIDA Res Monogr. 1990; 102:142–177.

    PubMed  CAS  Google Scholar 

  93. Friedl KE, Hannan CJ, Jr., Jones RE, Plymate SR. High-density lipoprotein cholesterol is not decreased if an aromatizable androgen is administered. Metabolism. 1990; 39:69–74.

    PubMed  CAS  Google Scholar 

  94. Whitsel EA, Boyko EJ, Matsumoto AM, Anawalt BD, Siscovick DS. Intramuscular testosterone esters and plasma lipids in hypogonadal men: a meta-analysis. Am J Med. 2001; 111:261–269.

    PubMed  CAS  Google Scholar 

  95. Isidori AM, Giannetta E, Greco EA, Gianfrilli D, Bonifacio V, Isidori A, Lenzi A, Fabbri A. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf). 2005; 63:280–293.

    CAS  Google Scholar 

  96. Singh AB, Hsia S, Alaupovic P, Sinha-Hikim I, Woodhouse L, Buchanan TA, Shen R, Bross R, Berman N, Bhasin S. The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men. J Clin Endocrinol Metab. 2002; 87:136–143.

    PubMed  CAS  Google Scholar 

  97. Jockenhovel F, Bullmann C, Schubert M, Vogel E, Reinhardt W, Reinwein D, Muller-Wieland D, Krone W. Influence of various modes of androgen substitution on serum lipids and lipoproteins in hypogonadal men. Metabolism. 1999; 48:590–596.

    PubMed  CAS  Google Scholar 

  98. Dickerman RD, McConathy WJ, Schaller F, Zachariah NY. Cardiovascular complications and anabolic steroids. Eur Heart J. 1996; 17:1912.

    PubMed  CAS  Google Scholar 

  99. Kennedy MC, Lawrence C. Anabolic steroid abuse and cardiac death. Med J Aust. 1993; 158:346–348.

    PubMed  CAS  Google Scholar 

  100. Payne JR, Kotwinski PJ, Montgomery HE. Cardiac effects of anabolic steroids. Heart (British Cardiac Society). 2004; 90:473–475.

    CAS  Google Scholar 

  101. De Piccoli B, Giada F, Benettin A, Sartori F, Piccolo E. Anabolic steroid use in body builders: an echocardiographic study of left ventricle morphology and function. Int J Sports Med. 1991; 12:408–412.

    PubMed  Google Scholar 

  102. Urhausen A, Albers T, Kindermann W. Are the cardiac effects of anabolic steroid abuse in strength athletes reversible? Heart (British Cardiac Society). 2004; 90:496–501.

    CAS  Google Scholar 

  103. Stolt A, Karila T, Viitasalo M, Mantysaari M, Kujala UM, Karjalainen J. QT interval and QT dispersion in endurance athletes and in power athletes using large doses of anabolic steroids. Am J Cardiol. 1999; 84:364–366, A369.

    PubMed  CAS  Google Scholar 

  104. Hausmann R, Hammer S, Betz P. Performance enhancing drugs (doping agents) and sudden death – a case report and review of the literature. Int J Legal Med. 1998; 111:261–264.

    PubMed  CAS  Google Scholar 

  105. Di Paolo M, Agozzino M, Toni C, Luciani AB, Molendini L, Scaglione M, Inzani F, Pasotti M, Buzzi F, Arbustini E. Sudden anabolic steroid abuse-related death in athletes. Int J Cardiol. 2007; 114:114–117.

    PubMed  Google Scholar 

  106. Dickerman RD, Schaller F, Prather I, McConathy WJ. Sudden cardiac death in a 20-year-old bodybuilder using anabolic steroids. Cardiology. 1995; 86:172–173.

    PubMed  CAS  Google Scholar 

  107. Fineschi V, Baroldi G, Monciotti F, Paglicci Reattelli L, Turillazzi E. Anabolic steroid abuse and cardiac sudden death: a pathologic study. Arch Pathol Lab Med. 2001; 125:253–255.

    PubMed  CAS  Google Scholar 

  108. Fineschi V, Riezzo I, Centini F, Silingardi E, Licata M, Beduschi G, Karch SB. Sudden cardiac death during anabolic steroid abuse: morphologic and toxicologic findings in two fatal cases of bodybuilders. Int J Legal Med. 2007; 121:48–53.

    PubMed  Google Scholar 

  109. Luke JL, Farb A, Virmani R, Sample RH. Sudden cardiac death during exercise in a weight lifter using anabolic androgenic steroids: pathological and toxicological findings. J Forensic Sci. 1990; 35:1441–1447.

    PubMed  CAS  Google Scholar 

  110. Pye M, Quinn AC, Cobbe SM. QT interval dispersion: a non-invasive marker of susceptibility to arrhythmia in patients with sustained ventricular arrhythmias? Br Heart J. 1994; 71:511–514.

    PubMed  CAS  Google Scholar 

  111. Tricker R, Casaburi R, Storer TW, Clevenger B, Berman N, Shirazi A, Bhasin S. The effects of supraphysiological doses of testosterone on angry behavior in healthy eugonadal men – a clinical research center study. J Clin Endocrinol Metab. 1996; 81:3754–3758.

    PubMed  CAS  Google Scholar 

  112. Su TP, Pagliaro M, Schmidt PJ, Pickar D, Wolkowitz O, Rubinow DR. Neuropsychiatric effects of anabolic steroids in male normal volunteers. JAMA. 1993; 269:2760–2764.

    PubMed  CAS  Google Scholar 

  113. Yates WR, Perry PJ, MacIndoe J, Holman T, Ellingrod V. Psychosexual effects of three doses of testosterone cycling in normal men. Biol Psychiatry. 1999; 45:254–260.

    PubMed  CAS  Google Scholar 

  114. Kouri EM, Lukas SE, Pope HG, Jr., Oliva PS. Increased aggressive responding in male ­volunteers following the administration of gradually increasing doses of testosterone cypionate. Drug Alcohol Depend. 1995; 40:73–79.

    PubMed  CAS  Google Scholar 

  115. Pope HG, Jr., Kouri EM, Hudson JI. Effects of supraphysiologic doses of testosterone on mood and aggression in normal men: a randomized controlled trial. Arch Gen Psychiatry. 2000; 57:133–140; discussion 155–136.

    PubMed  CAS  Google Scholar 

  116. Wang C, Alexander G, Berman N, Salehian B, Davidson T, McDonald V, Steiner B, Hull L, Callegari C, Swerdloff RS. Testosterone replacement therapy improves mood in hypogonadal men – a clinical research center study. J Clin Endocrinol Metab. 1996; 81:3578–3583.

    PubMed  CAS  Google Scholar 

  117. Midgley SJ, Heather N, Davies JB. Levels of aggression among a group of anabolic-androgenic steroid users. Med Sci Law. 2001; 41:309–314.

    PubMed  CAS  Google Scholar 

  118. Klotz F, Garle M, Granath F, Thiblin I. Criminality among individuals testing positive for the presence of anabolic androgenic steroids. Arch Gen Psychiatry. 2006; 63:1274–1279.

    PubMed  Google Scholar 

  119. Pope HG, Jr., Katz DL. Homicide and near-homicide by anabolic steroid users. J Clin Psychiatry. 1990; 51:28–31

    PubMed  Google Scholar 

  120. Malone DA, Jr., Dimeff RJ, Lombardo JA, Sample RH. Psychiatric effects and psychoactive substance use in anabolic-androgenic steroid users. Clin J Sport Med. 1995; 5:25–31.

    PubMed  Google Scholar 

  121. Uzych L. Anabolic-androgenic steroids and psychiatric-related effects: a review. Can J Psychiatry. 1992; 37:23–28.

    PubMed  CAS  Google Scholar 

  122. Porcerelli JH, Sandler BA. Anabolic-androgenic steroid abuse and psychopathology. Psychiatr Clin North Am. 1998; 21:829–833.

    PubMed  CAS  Google Scholar 

  123. Gruber A, Pope HG, Jr. Psychaitric and medical effects of anabolic-androgenic steroid use in women. Psychother Psychosom. 2000; 69:19–26.

    PubMed  CAS  Google Scholar 

  124. Kanayama G, Cohane GH, Weiss RD, Pope HG. Past anabolic-androgenic steroid use among men admitted for substance abuse treatment: an underrecognized problem? J Clin Psychiatry. 2003; 64:156–160.

    PubMed  Google Scholar 

  125. Cabasso A. Peliosis hepatis in a young adult bodybuilder. Med Sci Sports Exerc. 1994; 26:2–4.

    PubMed  CAS  Google Scholar 

  126. Socas L, Zumbado M, Perez-Luzardo O, Ramos A, Perez C, Hernandez JR, Boada LD. Hepatocellular adenomas associated with anabolic androgenic steroid abuse in bodybuilders: a report of two cases and a review of the literature. Br J Sports Med. 2005; 39:e27.

    PubMed  CAS  Google Scholar 

  127. Kosaka A, Takahashi H, Yajima Y, Tanaka M, Okamura K, Mizumoto R, Katsuta K. Hepatocellular carcinoma associated with anabolic steroid therapy: report of a case and review of the Japanese literature. J Gastroenterol. 1996; 31:450–454.

    PubMed  CAS  Google Scholar 

  128. Pavlatos AM, Fultz O, Monberg MJ, Pharmd VA. Review of oxymetholone: a 17alpha-alkylated anabolic-androgenic steroid. Clin Ther. 2001; 23:789–801; discussion 771.

    PubMed  CAS  Google Scholar 

  129. Calof O, Singh AB, Lee MJ, Urban RJ, Kenny AM, Tenover JL, Bhasin S. Adverse events associated with testosterone supplementation of older men. J Gerontol A Biol Sci Med Sci. 2005; 60: 1451–1457.

    PubMed  Google Scholar 

  130. Nakao A, Sakagami K, Nakata Y, Komazawa K, Amimoto T, Nakashima K, Isozaki H, Takakura N, Tanaka N. Multiple hepatic adenomas caused by long-term administration of androgenic steroids for aplastic anemia in association with familial adenomatous polyposis. J Gastroenterol. 2000; 35:557–562.

    PubMed  CAS  Google Scholar 

  131. Gill GV. Anabolic steroid induced hypogonadism treated with human chorionic gonadotropin. Postgrad Med J. 1998; 74:45–46.

    PubMed  CAS  Google Scholar 

  132. MacIndoe JH, Perry PJ, Yates WR, Holman TL, Ellingrod VL, Scott SD. Testosterone ­suppression of the HPT axis. J Investig Med. 1997; 45:441–447.

    PubMed  CAS  Google Scholar 

  133. Lloyd FH, Powell P, Murdoch AP. Anabolic steroid abuse by body builders and male subfertility. BMJ. 1996; 313:100–101.

    PubMed  CAS  Google Scholar 

  134. Jarow JP, Lipshultz LI. Anabolic steroid-induced hypogonadotropic hypogonadism. Am J Sports Med. 1990; 18:429–431.

    PubMed  CAS  Google Scholar 

  135. Brower KJ. Anabolic steroid abuse and dependence. Curr Psychiatry Rep. 2002; 4:377–387.

    PubMed  Google Scholar 

  136. Brower KJ, Blow FC, Young JP, Hill EM. Symptoms and correlates of anabolic-androgenic steroid dependence. Br J Addict. 1991; 86:759–768.

    PubMed  CAS  Google Scholar 

  137. Brower KJ, Eliopulos GA, Blow FC, Catlin DH, Beresford TP. Evidence for physical and psychological dependence on anabolic androgenic steroids in eight weight lifters. Am J Psychiatry. 1990; 147:510–512.

    PubMed  CAS  Google Scholar 

  138. Babigian A, Silverman RT. Management of gynecomastia due to use of anabolic steroids in bodybuilders. Plast Reconstr Surg. 2001; 107:240–242.

    PubMed  CAS  Google Scholar 

  139. Ding EL, Song Y, Manson JE, Hunter DJ, Lee CC, Rifai N, Buring JE, Gaziano JM, Liu S. Sex hormone-binding globulin and risk of type 2 diabetes in women and men. N Engl J Med. 2009; 361(12): 1152–1163

    PubMed  CAS  Google Scholar 

  140. Holmang A, Bjorntorp P. The effects of testosterone on insulin sensitivity in male rats. Acta Physiol Scand. 1992; 146:505–510.

    PubMed  CAS  Google Scholar 

  141. Cohen JC, Hickman R. Insulin resistance and diminished glucose tolerance in powerlifters ingesting anabolic steroids. J Clin Endocrinol Metab. 1987; 64:960–963.

    PubMed  CAS  Google Scholar 

  142. Wilson DM, Frane JW, Sherman B, Johanson AJ, Hintz RL, Rosenfeld RG. Carbohydrate and lipid metabolism in Turner syndrome: effect of therapy with growth hormone, oxandrolone, and a combination of both. J Pediatr. 1988; 112:210–217.

    PubMed  CAS  Google Scholar 

  143. Evans NA, Bowrey DJ, Newman GR. Ultrastructural analysis of ruptured tendon from ­anabolic steroid users. Injury. 1998; 29:769–773.

    PubMed  CAS  Google Scholar 

  144. Graham MR, Davies B, Grace FM, Kicman A, Baker JS. Anabolic steroid use: patterns of use and detection of doping. Sports Med. 2008; 38:505–525.

    PubMed  Google Scholar 

  145. Bhasin S, Singh AB, Mac RP, Carter B, Lee MI, Cunningham GR. Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan. J Androl. 2003; 24:299–311.

    PubMed  Google Scholar 

  146. Derman RJ. Effects of sex steroids on women’s health: implications for practitioners. Am J Med. 1995; 98:137S–143S.

    PubMed  CAS  Google Scholar 

  147. Ding EL, Song Y, Malik VS, Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA. 2006; 295:1288–1299.

    PubMed  CAS  Google Scholar 

  148. Casavant MJ, Blake K, Griffith J, Yates A, Copley LM. Consequences of use of anabolic androgenic steroids. Pediatr Clin North Am. 2007; 54:677–690, x.

    PubMed  Google Scholar 

  149. Rogol AD. Sex steroid and growth hormone supplementation to enhance performance in adolescent athletes. Curr Opin Pediatr. 2000; 12:382–387.

    PubMed  CAS  Google Scholar 

  150. vandenBerg P, Neumark-Sztainer D, Cafri G, Wall M. Steroid use among adolescents: ­longitudinal findings from project EAT. Pediatrics. 2007; 119:476–486.

    PubMed  Google Scholar 

  151. Jasuja R, Catlin DH, Miller A, Chang YC, Herbst KL, Starcevic B, Artaza JN, Singh R, Datta G, Sarkissian A, Chandsawangbhuwana C, Baker M, Bhasin S. Tetrahydrogestrinone is an androgenic steroid that stimulates androgen receptor-mediated, myogenic differentiation in C3H10T1/2 multipotent mesenchymal cells and promotes muscle accretion in orchidectomized male rats. Endocrinology. 2005; 146:4472–4478.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Boston Claude D. Pepper Older Americans Independence Center for Function Promoting Therapies, Section of Endocrinology, Diabetes, and Nutrition, Boston University, School of Medicine, Boston, MA, 02118, USA

    Shalender Bhasin

Authors
  1. Karen Choong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ravi Jasuja
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shehzad Basaria
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Thomas W. Storer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shalender Bhasin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shalender Bhasin .

Editor information

Editors and Affiliations

  1. , Division of Endocrinology, Diabetology a, University of Torino, Torino, 10126, Italy

    Ezio Ghigo

  2. , Division of Endocrinology, Diabetology a, University of Torino, Torino, 10126, Italy

    Fabio Lanfranco

  3. , Division of Clinical Endocrinology, Charité - Universitätsmedizin, Berlin, 10117, Germany

    Christian J. Strasburger

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Choong, K., Jasuja, R., Basaria, S., Storer, T.W., Bhasin, S. (2011). Androgen Abuse. In: Ghigo, E., Lanfranco, F., Strasburger, C. (eds) Hormone Use and Abuse by Athletes. Endocrine Updates, vol 29. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-7014-5_9

Download citation

  • DOI: https://doi.org/10.1007/978-1-4419-7014-5_9

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4419-7013-8

  • Online ISBN: 978-1-4419-7014-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation